Person · CIK 1197350

Eric Bjerkholt

CHIEF FINANCIAL OFFICER at Mirum Pharmaceuticals; director at Cerus, Metagenomi Therapeutics and Surrozen

Earlier: CalciMedica, Chinook Therapeutics, Aimmune Therapeutics, Corium International, Sunesis Pharmaceuticals and Stemcells

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$4.7M

Noticed on Form 144$3.5M

Bought on Form 4$981K

Companies10

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Mirum Pharmaceuticals MIRM	Common Stock	Directly	44,745	Sep 14, 2026 · Filing · EDGAR
Cerus CERS	Common Stock	Directly	261,679	Jun 9, 2026 · Filing · EDGAR
Cerus CERS	Option (Right to Buy) exercise $4.84, expires May 31, 2032, into Common Stock	Directly	39,866	Jun 1, 2022 · Filing · EDGAR
Metagenomi Therapeutics MGX	Stock Option (Right to Buy) exercise $1.23, expires Jun 8, 2036, into Common Stock	Directly	21,000	Jun 9, 2026 · Filing · EDGAR
Surrozen SRZN	Director Stock Option (right to buy) exercise $30.14, expires May 12, 2036, into Common Stock	Directly	5,550	May 13, 2026 · Filing · EDGAR
CalciMedica	Common Stock	Directly	3,684	May 31, 2023 · Filing · EDGAR
CalciMedica	Director Stock Option (Right to Buy) exercise $4.16, expires Aug 26, 2034, into Common Stock	Directly	10,000	Aug 27, 2024 · Filing · EDGAR
Sunesis Pharmaceuticals	Common Stock	Directly	23,417	Nov 30, 2016 · Filing · EDGAR
Sunesis Pharmaceuticals	Common Stock	See footnote	83,827	Jul 24, 2015 · Filing · EDGAR
Sunesis Pharmaceuticals	Commmon Stock	See footnote.	83,827	Feb 29, 2016 · Filing · EDGAR
Sunesis Pharmaceuticals	Common Stock	See footnote.	13,971	Nov 30, 2016 · Filing · EDGAR
Sunesis Pharmaceuticals	Stock Option (Right to Buy) exercise $4.00, expires Nov 30, 2026, into Common Stock	Directly	95,000	Nov 30, 2016 · Filing · EDGAR
Stemcells	Common Stock	Directly	273,759	Jan 1, 2016 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q3 2026	$2.2M	$2.2M	—
Q2 2026	$522K	$522K	—
Q1 2026	$904K	$777K	—
Q3 2025	$728K	—	—
Q4 2024	$36K	$36K	—
Q1 2024	—	—	$101K
Q4 2023	—	—	$16K
Q3 2023	—	—	$314K
Q2 2023	—	—	$17K
Q1 2023	$92K	Not machine-readable	—
Q4 2022	$129K	Not machine-readable	—
Q1 2022	$11K	Not machine-readable	—
Q1 2020	—	—	$117K
Q3 2019	—	—	$35K
Q2 2018	—	—	$49K
Q1 2018	—	—	$100K
Q2 2017	—	—	$99K
Q2 2016	—	—	$89K
Q3 2015	$22K	Not machine-readable	—
Q3 2014	$80K	Not machine-readable	—
Q4 2010	—	—	$31K
Q1 2007	—	—	$13K

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 2 notices
Sep 15, 2026	9,943 · ~$978K	Sep 14, 2026	Sold as noticed Sold 9,943 at $98.37 on Sep 14 · $978K Form 4	Filing · EDGAR
Aug 11, 2026	6,001 · ~$600K	Aug 11, 2026	Sold as noticed Sold 6,001 at $99.90 on Aug 11 · $600K Form 4	Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 9, 2026 · 2 notices
Jul 6, 2026	5,000 · ~$611K	Jul 6, 2026	Sold as noticed Sold 5,000 in 4 sales, Jul 6 to Jul 6 · $611K Form 4	Filing · EDGAR
Jun 8, 2026	5,000 · ~$469K	Jun 8, 2026	Sold as noticed Sold 5,000 in 3 sales, Jun 8 to Jun 8 · $469K Form 4	Filing · EDGAR
Cerus CERS · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Jun 9, 2026	20,454 · ~$53K	Jun 9, 2026	Sold as noticed Sold 20,454 at $2.60 on Jun 9 · $53K Form 4	Filing · EDGAR
Mirum Pharmaceuticals MIRM · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jan 23, 2024 · 2 notices
Mar 17, 2026	7,287 · ~$675K	Mar 16, 2026	Sold as noticed Sold 7,287 at $91.98 on Mar 16 · $670K Form 4	Filing · EDGAR
Jan 28, 2026	1,053 · ~$102K	Jan 26, 2026	Sold as noticed Sold 1,053 at $96.19 on Jan 26 · $101K Form 4	Filing · EDGAR
Cerus CERS · Merrill Lynch · No 10b5-1 plan stated · 1 notice
Dec 12, 2024	20,000 · ~$36K	Dec 12, 2024	Sold as noticed Sold 20,000 at $1.79 on Dec 12 · $36K Form 4	Filing · EDGAR
Sales without a matching Form 144 · 10 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 1,421 at $93.33 on Jan 22, 2026 · $133K	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 9,578 at $76.01 on Sep 12, 2025 · $728K	Filing · EDGAR
—	—	—	Sold without notice Mirum Pharmaceuticals (MIRM): Sold 8,000 on Aug 11, 2025	Filing · EDGAR
—	—	—	Notice not machine-readable Chinook Therapeutics: Sold 857 at $23.75 on Feb 10, 2023 · $20K	Filing · EDGAR
—	—	—	Notice not machine-readable Chinook Therapeutics: Sold 2,891 at $24.68 on Jan 31, 2023 · $71K	Filing · EDGAR
—	—	—	Notice not machine-readable Chinook Therapeutics: Sold 5,770 at $22.29 on Dec 1, 2022 · $129K	Filing · EDGAR
—	—	—	Notice not machine-readable Chinook Therapeutics: Sold 895 at $12.74 on Feb 11, 2022 · $11K	Filing · EDGAR
—	—	—	Notice not machine-readable Sunesis Pharmaceuticals: Sold 2,119 at $3.46 on Jul 24, 2015 · $7K	Filing · EDGAR
—	—	—	Notice not machine-readable Sunesis Pharmaceuticals: Sold 4,239 at $3.46 on Jul 24, 2015 · $15K	Filing · EDGAR
—	—	—	Notice not machine-readable Sunesis Pharmaceuticals: Sold 10,000 at $8.00 on Aug 27, 2014 · $80K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Mirum Pharmaceuticals MIRM Chief financial officer · filings 2023 to 2026 · sold $4.3M · bought $398K · $3.4M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 14, 2026	Open-market or private sale	−9,943	$98.37	$978K	44,745 direct	Filing · EDGAR
Sep 11, 2026	Option or RSU exercised or converted	+18,333			54,688 direct	Filing · EDGAR
Sep 11, 2026	Option or RSU exercised or converted Restricted Stock Units	−18,333			0 direct	Filing · EDGAR
Aug 11, 2026	Sale under a 10b5-1 plan	−6,001	$99.90	$600K	36,355 direct	Filing · EDGAR
Jul 6, 2026	Sale under a 10b5-1 plan	−3,124	$121.67	$380K	44,057 direct	Filing · EDGAR
Jul 6, 2026	Sale under a 10b5-1 plan	−1,048	$122.43	$128K	43,009 direct	Filing · EDGAR
Jul 6, 2026	Sale under a 10b5-1 plan	−528	$123.84	$65K	42,481 direct	Filing · EDGAR
Jul 6, 2026	Sale under a 10b5-1 plan	−300	$124.94	$37K	42,181 direct	Filing · EDGAR
Jun 9, 2026	Option or RSU exercised or converted	+2,393	$26.49	$63K	47,181 direct	Filing · EDGAR
Jun 9, 2026	Option or RSU exercised or converted Employee Stock Option (right to buy)	−2,393			26,653 direct	Filing · EDGAR
Jun 8, 2026	Sale under a 10b5-1 plan	−2,258	$92.84	$210K	47,530 direct	Filing · EDGAR
Jun 8, 2026	Sale under a 10b5-1 plan	−1,175	$93.95	$110K	46,355 direct	Filing · EDGAR
Jun 8, 2026	Sale under a 10b5-1 plan	−1,567	$95.12	$149K	44,788 direct	Filing · EDGAR
Mar 16, 2026	Open-market or private sale	−7,287	$91.98	$670K	49,788 direct	Filing · EDGAR
Mar 15, 2026	Option or RSU exercised or converted	+13,334			57,075 direct	Filing · EDGAR
Mar 15, 2026	Option or RSU exercised or converted Performance Restricted Stock Units	−13,334			6,666 direct	Filing · EDGAR
Jan 28, 2026	Grant or award from the company Stock Option (right to buy)	+18,140			18,140 direct	Filing · EDGAR
Jan 28, 2026	Grant or award from the company Restricted Stock Units	+11,760			11,760 direct	Filing · EDGAR
Jan 28, 2026	Grant or award from the company Performance Restricted Stock Units	+20,000			20,000 direct	Filing · EDGAR
Jan 26, 2026	Open-market or private sale	−1,053	$96.19	$101K	43,741 direct	Filing · EDGAR
Jan 23, 2026	Option or RSU exercised or converted	+2,667			44,794 direct	Filing · EDGAR
Jan 23, 2026	Option or RSU exercised or converted Restricted Stock Units	−2,667			2,666 direct	Filing · EDGAR
Jan 22, 2026	Open-market or private sale	−1,421	$93.33	$133K	42,127 direct	Filing · EDGAR
Jan 21, 2026	Option or RSU exercised or converted	+3,334			43,548 direct	Filing · EDGAR
Jan 21, 2026	Option or RSU exercised or converted Restricted Stock Units	−3,334			6,666 direct	Filing · EDGAR
Sep 12, 2025	Open-market or private sale	−9,578	$76.01	$728K	39,945 direct	Filing · EDGAR
Sep 11, 2025	Option or RSU exercised or converted	+18,333			49,523 direct	Filing · EDGAR
Sep 11, 2025	Option or RSU exercised or converted Restricted Stock Units	−18,333			18,333 direct	Filing · EDGAR
Aug 12, 2025	Option or RSU exercised or converted	+2,954	$26.49	$78K	31,190 direct	Filing · EDGAR
Aug 12, 2025	Option or RSU exercised or converted Employee Stock Option (right to buy)	−2,954			29,046 direct	Filing · EDGAR
Aug 11, 2025	Open-market or private sale	−8,000			28,236 direct	Filing · EDGAR
Jan 23, 2025	Option or RSU exercised or converted	+2,667			35,946 direct	Filing · EDGAR
Jan 23, 2025	Option or RSU exercised or converted Restricted Stock Units	−2,667			5,333 direct	Filing · EDGAR
Jan 21, 2025	Grant or award from the company Stock Option (right to buy)	+40,000			40,000 direct	Filing · EDGAR
Jan 21, 2025	Grant or award from the company Restricted Stock Units	+10,000			10,000 direct	Filing · EDGAR
Nov 8, 2024	Grant or award from the company	+475	$21.05	$10K	33,279 direct	Filing · EDGAR
Sep 11, 2024	Option or RSU exercised or converted	+18,334			32,804 direct	Filing · EDGAR
Sep 11, 2024	Option or RSU exercised or converted Restricted Stock Units	−18,334			36,666 direct	Filing · EDGAR
May 10, 2024	Grant or award from the company	+470	$21.05	$10K	14,470 direct	Filing · EDGAR
Mar 27, 2024	Open-market or private purchase	+2,000	$24.80	$50K	14,000 direct	Filing · EDGAR
Mar 18, 2024	Open-market or private purchase	+2,000	$25.80	$52K	12,000 direct	Filing · EDGAR
Jan 23, 2024	Grant or award from the company Stock Option (right to buy)	+32,000			32,000 direct	Filing · EDGAR
Jan 23, 2024	Grant or award from the company Restricted Stock Units	+8,000			8,000 direct	Filing · EDGAR
Sep 11, 2023	Open-market or private purchase	+10,000	$29.65	$296K	10,000 direct	Filing · EDGAR
Sep 11, 2023	Grant or award from the company Stock Option (right to buy)	+110,000			110,000 direct	Filing · EDGAR
Sep 11, 2023	Grant or award from the company Restricted Stock Units	+55,000			55,000 direct	Filing · EDGAR

Cerus CERS Director · filings 2018 to 2026 · sold $89K · bought $126K · $89K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 9, 2026	Open-market or private sale	−20,454	$2.60	$53K	261,679 direct	Filing · EDGAR
Jun 2, 2026	Grant or award from the company	+60,000			282,133 direct	Filing · EDGAR
Jun 3, 2025	Grant or award from the company	+60,000			222,133 direct	Filing · EDGAR
Dec 12, 2024	Open-market or private sale	−20,000	$1.79	$36K	162,133 direct	Filing · EDGAR
Jun 5, 2024	Grant or award from the company	+40,000	$5.00	$200K	182,133 direct	Filing · EDGAR
Dec 13, 2023	Open-market or private purchase	+10,000	$1.62	$16K	142,133 direct	Filing · EDGAR
Aug 21, 2023	Open-market or private purchase	+10,000	$1.72	$17K	132,133 direct	Filing · EDGAR
Jun 7, 2023	Grant or award from the company	+40,000	$5.00	$200K	122,133 direct	Filing · EDGAR
May 23, 2023	Open-market or private purchase	+5,000	$2.00	$10K	82,133 direct	Filing · EDGAR
Jun 1, 2022	Grant or award from the company	+20,454			77,133 direct	Filing · EDGAR
Jun 1, 2022	Grant or award from the company Option (Right to Buy)	+39,866			39,866 direct	Filing · EDGAR
Jun 2, 2021	Grant or award from the company	+14,888			56,679 direct	Filing · EDGAR
Jun 2, 2021	Grant or award from the company Option (Right to Buy)	+29,983			29,983 direct	Filing · EDGAR
Jun 1, 2021	Option or RSU exercised or converted	+13,228			41,791 direct	Filing · EDGAR
Jun 1, 2021	Option or RSU exercised or converted Restricted Stock Unit	−13,228			0 direct	Filing · EDGAR
Oct 5, 2020	Option or RSU exercised or converted	+4,281			28,563 direct	Filing · EDGAR
Oct 5, 2020	Option or RSU exercised or converted Restricted Stock Unit	−4,281			4,281 direct	Filing · EDGAR
Jun 3, 2020	Grant or award from the company Option (Right to Buy)	+28,177			28,177 direct	Filing · EDGAR
Jun 3, 2020	Grant or award from the company Restricted Stock Unit	+13,228			13,228 direct	Filing · EDGAR
Jan 29, 2020	Open-market or private purchase	+20,000	$4.15	$83K	24,282 direct	Filing · EDGAR
Oct 4, 2019	Option or RSU exercised or converted	+4,282			4,282 direct	Filing · EDGAR
Oct 4, 2019	Option or RSU exercised or converted Restricted Stock Unit	−4,282			8,562 direct	Filing · EDGAR
Jun 5, 2019	Grant or award from the company Option (Right to Buy)	+23,703			23,703 direct	Filing · EDGAR
Jun 5, 2019	Grant or award from the company Restricted Stock Unit	+11,184			11,184 direct	Filing · EDGAR
Oct 5, 2018	Grant or award from the company Option (Right to Buy)	+24,013			24,013 direct	Filing · EDGAR
Oct 5, 2018	Grant or award from the company Restricted Stock Units	+12,844			12,844 direct	Filing · EDGAR

Metagenomi Therapeutics MGX Director · filings 2025 to 2026

Date	Transaction	Shares	Held after	Source
Jun 9, 2026	Grant or award from the company Stock Option (Right to Buy)	+21,000	21,000 direct	Filing · EDGAR
Jun 10, 2025	Grant or award from the company Stock Option (Right to Buy)	+8,572	8,572 direct	Filing · EDGAR
Feb 3, 2025	Grant or award from the company Stock Option (Right to Buy)	+42,000	42,000 direct	Filing · EDGAR

Surrozen SRZN Director · filings 2023 to 2026

Date	Transaction	Shares	Held after	Source
May 13, 2026	Grant or award from the company Director Stock Option (right to buy)	+5,550	5,550 direct	Filing · EDGAR
May 14, 2025	Grant or award from the company Option (right to buy)	+1,333	1,333 direct	Filing · EDGAR
Jun 5, 2024	Grant or award from the company Option (right to buy)	+1,333	1,333 direct	Filing · EDGAR
May 18, 2023	Grant or award from the company Option (right to buy)	+20,000	20,000 direct	Filing · EDGAR

CalciMedica Director · filings 2020 to 2024 · bought $7K

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 27, 2024	Grant or award from the company Director Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Mar 28, 2024	Grant or award from the company Director Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
May 31, 2023	Open-market or private purchase	+100	$4.09	$409	3,534 direct	Filing · EDGAR
May 31, 2023	Open-market or private purchase	+150	$4.20	$630	3,684 direct	Filing · EDGAR
May 30, 2023	Open-market or private purchase	+5	$3.25	$16	3,434 direct	Filing · EDGAR
May 23, 2023	Open-market or private purchase	+500	$3.27	$2K	3,429 direct	Filing · EDGAR
May 19, 2023	Open-market or private purchase	+199	$2.65	$527	2,929 direct	Filing · EDGAR
May 18, 2023	Open-market or private purchase	+1	$2.65	$3	2,730 direct	Filing · EDGAR
May 18, 2023	Open-market or private purchase	+300	$2.70	$810	2,729 direct	Filing · EDGAR
May 17, 2023	Open-market or private purchase	+200	$2.67	$534	2,429 direct	Filing · EDGAR
May 16, 2023	Open-market or private purchase	+800	$2.70	$2K	2,229 direct	Filing · EDGAR
May 8, 2023	Grant or award from the company Director Stock Option (Right to Buy)	+20,000			20,000 direct	Filing · EDGAR
Mar 23, 2023	Returned to the company	+1,429			1,429 direct	Filing · EDGAR
Mar 23, 2023	Returned to the company Restricted Stock Unit	−1,429			0 direct	Filing · EDGAR
Jun 2, 2022	Grant or award from the company Stock Option (Right to Buy)	+20,000			20,000 direct	Filing · EDGAR
Jun 2, 2022	Grant or award from the company Restricted Stock Units	+20,000			20,000 direct	Filing · EDGAR
Jun 2, 2021	Grant or award from the company Employee Stock Option (Right to Buy)	+12,500			12,500 direct	Filing · EDGAR
Sep 24, 2020	Grant or award from the company Director Stock Option (Right to Buy)	+25,000			25,000 direct	Filing · EDGAR

Chinook Therapeutics Chief Financial Officer · filings 2020 to 2023 · sold $232K

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 11, 2023	Returned to the company	−39,371			0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Stock Option (Right to Buy)	−144,787	$26.02	$3.8M	0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Stock Option (Right to Buy)	−21,501	$24.86	$535K	0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Stock Option (Right to Buy)	−88,000	$27.10	$2.4M	0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Stock Option (Right to Buy)	−84,000	$14.73	$1.2M	0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Restricted Stock Units	−16,415			0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Restricted Stock Units	−2,435			0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Restricted Stock Units	−14,667			0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Restricted Stock Units	−21,000			0 direct	Filing · EDGAR
Aug 11, 2023	Returned to the company Restricted Stock Units	−8,400			0 direct	Filing · EDGAR
Feb 10, 2023	Option or RSU exercised or converted	+2,435			39,724 direct	Filing · EDGAR
Feb 10, 2023	Open-market or private sale	−857	$23.75	$20K	38,867 direct	Filing · EDGAR
Feb 10, 2023	Option or RSU exercised or converted Restricted Stock Units	−2,435			2,435 direct	Filing · EDGAR
Jan 31, 2023	Option or RSU exercised or converted	+7,333			40,180 direct	Filing · EDGAR
Jan 31, 2023	Open-market or private sale	−2,891	$24.68	$71K	37,289 direct	Filing · EDGAR
Jan 31, 2023	Option or RSU exercised or converted Restricted Stock Unirt	−7,333			14,667 direct	Filing · EDGAR
Jan 31, 2023	Grant or award from the company Stock Option (Right to Buy)	+84,000			84,000 direct	Filing · EDGAR
Jan 31, 2023	Grant or award from the company Restricted Stock Unit	+21,000			21,000 direct	Filing · EDGAR
Dec 1, 2022	Open-market or private sale	−5,770	$22.29	$129K	32,847 direct	Filing · EDGAR
Nov 30, 2022	Option or RSU exercised or converted	+16,414			38,617 direct	Filing · EDGAR
Nov 30, 2022	Option or RSU exercised or converted Restricted Stock Units	−16,414			16,415 direct	Filing · EDGAR
Feb 11, 2022	Open-market or private sale	−895	$12.74	$11K	22,203 direct	Filing · EDGAR
Feb 10, 2022	Option or RSU exercised or converted	+2,434			23,098 direct	Filing · EDGAR
Feb 10, 2022	Option or RSU exercised or converted Restricted Stock Units (RSU)	−2,434			4,870 direct	Filing · EDGAR
Jan 31, 2022	Grant or award from the company Stock Option (right to buy)	+88,000			88,000 direct	Filing · EDGAR
Jan 31, 2022	Grant or award from the company Restricted Stock (RSU)(Common Stock)	+22,000			22,000 direct	Filing · EDGAR
Dec 1, 2021	Option or RSU exercised or converted	+16,414			26,414 direct	Filing · EDGAR
Dec 1, 2021	Shares withheld for tax or exercise price	−5,750	$16.02	$92K	20,664 direct	Filing · EDGAR
Dec 1, 2021	Option or RSU exercised or converted Restricted Stock Units (RSU)	−16,414			32,829 direct	Filing · EDGAR
Feb 10, 2021	Grant or award from the company Stock Option (right to buy)	+21,501			21,501 direct	Filing · EDGAR
Feb 10, 2021	Grant or award from the company Restricted Stock (RSU)(Common Stock)	+7,304			7,304 direct	Filing · EDGAR
Nov 30, 2020	Grant or award from the company Employee Stock Option (right to buy)	+144,787			144,787 direct	Filing · EDGAR
Nov 30, 2020	Grant or award from the company Restricted Stock Units	+49,243			49,243 direct	Filing · EDGAR

Aimmune Therapeutics Chief Financial Officer · filings 2017 to 2020 · bought $317K

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 13, 2020	Returned to the company	−23,905	$34.50	$825K	0 direct	Filing · EDGAR
Oct 13, 2020	Returned to the company Stock Option (right to buy)	−264,800	$15.06	$4M	0 direct	Filing · EDGAR
Oct 13, 2020	Returned to the company Stock Option (right to buy)	−56,250	$0.43	$24K	0 direct	Filing · EDGAR
Oct 13, 2020	Returned to the company Stock Option (right to buy)	−78,750	$10.78	$849K	0 direct	Filing · EDGAR
Oct 13, 2020	Returned to the company Stock Option (right to buy)	−56,250	$10.69	$601K	0 direct	Filing · EDGAR
Oct 10, 2020	Tendered in a change of control	−27,805	$34.50	$959K	0 direct	Filing · EDGAR
Oct 5, 2020	Option or RSU exercised or converted	+5,200	$19.44	$101K	49,841 direct	Filing · EDGAR
Oct 5, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,200			264,800 direct	Filing · EDGAR
Sep 15, 2020	Shares withheld for tax or exercise price	−840	$34.25	$29K	44,547 direct	Filing · EDGAR
May 10, 2020	Grant or award from the company	+2,420			45,387 direct	Filing · EDGAR
Mar 12, 2020	Open-market or private purchase	+1,000	$15.10	$15K	42,967 direct	Filing · EDGAR
Mar 9, 2020	Open-market or private purchase	+1,000	$18.97	$19K	41,967 direct	Filing · EDGAR
Mar 2, 2020	Shares withheld for tax or exercise price	−1,982	$23.81	$47K	40,967 direct	Filing · EDGAR
Feb 28, 2020	Grant or award from the company	+9,375			42,949 direct	Filing · EDGAR
Feb 28, 2020	Grant or award from the company Stock Option (right to buy)	+56,250			56,250 direct	Filing · EDGAR
Sep 18, 2019	Open-market or private purchase	+1,550	$22.57	$35K	33,574 direct	Filing · EDGAR
Mar 1, 2019	Shares withheld for tax or exercise price	−833	$24.30	$20K	32,741 direct	Filing · EDGAR
Feb 22, 2019	Grant or award from the company	+13,125			32,857 direct	Filing · EDGAR
Feb 22, 2019	Grant or award from the company Stock Option (right to buy)	+78,750			78,750 direct	Filing · EDGAR
Jun 13, 2018	Open-market or private purchase	+1,600	$30.41	$49K	19,485 direct	Filing · EDGAR
Mar 4, 2018	Grant or award from the company	+9,375			17,500 direct	Filing · EDGAR
Mar 4, 2018	Grant or award from the company Stock Option (right to buy)	+56,250			56,250 direct	Filing · EDGAR
Feb 26, 2018	Open-market or private purchase	+3,125	$32.00	$100K	8,125 direct	Filing · EDGAR
May 12, 2017	Open-market or private purchase	+5,000	$19.84	$99K	5,000 direct	Filing · EDGAR
Apr 28, 2017	Grant or award from the company Stock Option (right to buy)	+270,000			270,000 direct	Filing · EDGAR

Corium International Director · filings 2015 to 2018 · bought $89K

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 27, 2018	Returned to the company	−12,500	$12.50	$156K	0 By The Bjerkholt Family Irrevocable Trust	Filing · EDGAR
Nov 27, 2018	Returned to the company	−12,000	$12.50	$150K	0 By The Bjerkholt Children's Irrevocable Trust	Filing · EDGAR
Nov 27, 2018	Returned to the company Director Stock Option (Right to Buy)	−20,000	$12.50	$250K	0 direct	Filing · EDGAR
Nov 27, 2018	Returned to the company Director Stock Option (Right to Buy)	−12,000	$12.50	$150K	0 direct	Filing · EDGAR
Nov 27, 2018	Returned to the company Director Stock Option (Right to Buy)	−15,000	$12.50	$188K	0 direct	Filing · EDGAR
Nov 27, 2018	Returned to the company Director Stock Option (Right to Buy)	−15,000	$12.50	$188K	0 direct	Filing · EDGAR
Dec 1, 2017	Grant or award from the company Director Stock Option (Right to Buy)	+15,000			15,000 direct	Filing · EDGAR
Dec 22, 2016	Grant or award from the company Director Stock Option (Right to Buy)	+15,000			15,000 direct	Filing · EDGAR
May 19, 2016	Open-market or private purchase	+7,790	$3.71	$29K	12,500 By the Bjerkholt Family Irrevocable Trust	Filing · EDGAR
May 19, 2016	Open-market or private purchase	+6,341	$3.70	$23K	12,000 By the Bjerkholt Children's Irrevocable Trust	Filing · EDGAR
May 18, 2016	Open-market or private purchase	+4,710	$3.54	$17K	4,710 By the Bjerkholt Family Irrevocable Trust	Filing · EDGAR
May 18, 2016	Open-market or private purchase	+5,659	$3.57	$20K	5,659 By the Bjerkholt Children's Irrevocable Trust	Filing · EDGAR
Dec 18, 2015	Grant or award from the company Director Stock Option (right to buy)	+12,000			12,000 direct	Filing · EDGAR
Apr 14, 2015	Grant or award from the company Director Stock Option (right to buy)	+20,000			20,000 direct	Filing · EDGAR

Sunesis Pharmaceuticals EVP, CFO & Corp. Secretary · filings 2005 to 2016 · sold $102K · bought $44K

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 30, 2016	Grant or award from the company Stock Option (Right to Buy)	+95,000			95,000 direct	Filing · EDGAR
Feb 29, 2016	Grant or award from the company	+80,000			135,913 direct	Filing · EDGAR
Feb 29, 2016	Shares withheld for tax or exercise price	−34,991	$0.75	$26K	100,922 direct	Filing · EDGAR
Nov 30, 2015	Grant or award from the company Stock Option (Right to Buy)	+270,000			270,000 direct	Filing · EDGAR
Jul 24, 2015	In-the-money option exercised	+11,105	$1.32	$15K	84,634 See footnote	Filing · EDGAR
Jul 24, 2015	Open-market or private sale	−4,239	$3.46	$15K	80,395 See footnote	Filing · EDGAR
Jul 24, 2015	In-the-money option exercised	+5,551	$1.32	$7K	85,946 See footnote	Filing · EDGAR
Jul 24, 2015	Open-market or private sale	−2,119	$3.46	$7K	83,827 See footnote	Filing · EDGAR
Jul 24, 2015	In-the-money option exercised Warrant (right to buy)	−11,105			0 See footnote	Filing · EDGAR
Jul 24, 2015	In-the-money option exercised Warrant (right to buy)	−5,551			0 See footnote	Filing · EDGAR
Feb 27, 2015	Grant or award from the company	+17,642			57,636 direct	Filing · EDGAR
Feb 27, 2015	Shares withheld for tax or exercise price	−7,723	$2.22	$17K	49,913 direct	Filing · EDGAR
Oct 31, 2014	Grant or award from the company Stock Option (Right to Buy)	+140,000			140,000 direct	Filing · EDGAR
Aug 27, 2014	Option or RSU exercised or converted	+10,000	$1.74	$17K	49,994 direct	Filing · EDGAR
Aug 27, 2014	Sale under a 10b5-1 plan	−10,000	$8.00	$80K	39,994 direct	Filing · EDGAR
Aug 27, 2014	Option or RSU exercised or converted Stock Option (right to buy)	−10,000			115,000 direct	Filing · EDGAR
Feb 28, 2014	Grant or award from the company Stock Option Right to Buy	+125,000			125,000 direct	Filing · EDGAR
Feb 28, 2013	Grant or award from the company	+7,088			36,593 direct	Filing · EDGAR
Feb 28, 2013	Shares withheld for tax or exercise price	−2,599	$5.22	$14K	33,994 direct	Filing · EDGAR
Feb 28, 2013	Grant or award from the company Stock Option (Right to Buy)	+100,000			100,000 direct	Filing · EDGAR
Feb 29, 2012	Grant or award from the company	+17,349			32,222 direct	Filing · EDGAR
Feb 29, 2012	Shares withheld for tax or exercise price	−6,363	$1.74	$11K	25,859 direct	Filing · EDGAR
Feb 29, 2012	Grant or award from the company Stock Option (Right to Buy)	+125,000			125,000 direct	Filing · EDGAR
Jun 30, 2011	Grant or award from the company Stock Option (Right to Buy)	+450,000			450,000 direct	Filing · EDGAR
Feb 28, 2011	Grant or award from the company	+11,383			15,728 direct	Filing · EDGAR
Feb 28, 2011	Shares withheld for tax or exercise price	−4,175	$2.10	$9K	11,553 direct	Filing · EDGAR
Oct 8, 2010	Open-market or private purchase	+100,000	$0.31	$31K	438,183 See footnote	Filing · EDGAR
Jul 30, 2010	Grant or award from the company	+31,546			37,641 direct	Filing · EDGAR
Jul 30, 2010	Shares withheld for tax or exercise price	−11,571			26,070 direct	Filing · EDGAR
Jun 30, 2010	Open-market or private purchase	+238,243			238,243 See Footnote	Filing · EDGAR
Jun 30, 2010	Derivative converted	+99,940			338,183 See Footnote	Filing · EDGAR
Jun 30, 2010	Derivative converted Series A Preferred Stock	−9,994			0 See Footnote	Filing · EDGAR
Oct 30, 2009	Open-market or private purchase Series A Preferred Stock	+3,331	$2.20	$7K	9,994 See footnote	Filing · EDGAR
Oct 30, 2009	Open-market or private purchase Common Stock Purchase Warrant	+33,310	$0.13	$4K	33,310 See footnote	Filing · EDGAR
Aug 31, 2009	Grant or award from the company Stock Option (Right to Buy)	+450,000			450,000 direct	Filing · EDGAR
Apr 3, 2009	Open-market or private purchase Series A Preferred Stock	+6,663	$2.20	$15K	6,663 See footnote	Filing · EDGAR
Apr 3, 2009	Open-market or private purchase Common Stock Purchase Warrant	+66,630			66,630 See footnote	Filing · EDGAR
Jun 30, 2008	Grant or award from the company Stock Option (Right-to-Buy)	+67,500			67,500 direct	Filing · EDGAR
Sep 13, 2007	Grant or award from the company Employee Stock Option (right to buy)	+90,000			90,000 direct	Filing · EDGAR
Mar 13, 2007	Open-market or private purchase	+3,000	$4.30	$13K	5,567 direct	Filing · EDGAR
Oct 13, 2006	Grant or award from the company Employee Stock Option (right to buy)	+60,000			60,000 direct	Filing · EDGAR
Nov 29, 2005	Grant or award from the company Employee Stock Option (right to buy)	+120,000			120,000 direct	Filing · EDGAR

Stemcells Director · filings 2004 to 2016

Date	Transaction	Shares	Held after	Source
Jan 1, 2016	Grant or award from the company	+146,342	273,759 direct	Filing · EDGAR
Jan 1, 2015	Grant or award from the company	+58,253	127,417 direct	Filing · EDGAR
Jan 1, 2014	Grant or award from the company	+47,164	69,164 direct	Filing · EDGAR
Mar 1, 2013	Grant or award from the company	+10,000	22,000 direct	Filing · EDGAR
Apr 18, 2012	Grant or award from the company	+9,000	12,000 direct	Filing · EDGAR
Mar 1, 2012	Grant or award from the company	+1,000	3,000 direct	Filing · EDGAR
Mar 1, 2011	Grant or award from the company	+10,000	20,000 direct	Filing · EDGAR
Mar 1, 2010	Grant or award from the company	+10,000	10,000 direct	Filing · EDGAR
Mar 1, 2009	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Mar 1, 2008	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Mar 1, 2007	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Mar 1, 2006	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Mar 1, 2006	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
Mar 1, 2005	Grant or award from the company Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR

All 143 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Sep 15, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 15, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 12, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 11, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 8, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jul 6, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 11, 2026	Form 4	Cerus CERS	Filing · EDGAR
Jun 11, 2026	Form 4	Metagenomi Therapeutics MGX	Filing · EDGAR
Jun 9, 2026	Form 144	Cerus CERS	Filing · EDGAR
Jun 9, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 8, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 2, 2026	Form 4	Cerus CERS	Filing · EDGAR
May 14, 2026	Form 4	Surrozen SRZN	Filing · EDGAR
Mar 17, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 17, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 30, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 28, 2026	Form 144	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 27, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 23, 2026	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 12, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 12, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jun 12, 2025	Form 4	Metagenomi Therapeutics MGX	Filing · EDGAR
Jun 4, 2025	Form 4	Cerus CERS	Filing · EDGAR
May 15, 2025	Form 4	Surrozen SRZN	Filing · EDGAR
Feb 5, 2025	Form 4	Metagenomi Therapeutics MGX	Filing · EDGAR
Jan 27, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 27, 2025	Form 3	Metagenomi Therapeutics MGX	Filing · EDGAR
Jan 23, 2025	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 16, 2024	Form 4	Cerus CERS	Filing · EDGAR
Dec 12, 2024	Form 144	Cerus CERS	Filing · EDGAR
Nov 14, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 12, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 28, 2024	Form 4	CalciMedica	Filing · EDGAR
Jun 6, 2024	Form 4	Surrozen SRZN	Filing · EDGAR
Jun 6, 2024	Form 4	Cerus CERS	Filing · EDGAR
May 16, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Apr 22, 2024	Form 4	CalciMedica	Filing · EDGAR
Mar 27, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Mar 18, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Jan 25, 2024	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Dec 13, 2023	Form 4	Cerus CERS	Filing · EDGAR
Sep 12, 2023	Form 4	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Sep 12, 2023	Form 3	Mirum Pharmaceuticals MIRM	Filing · EDGAR
Aug 23, 2023	Form 4	Cerus CERS	Filing · EDGAR
Aug 11, 2023	Form 4	Chinook Therapeutics	Filing · EDGAR
Jun 28, 2023	Form 4	CalciMedica	Filing · EDGAR
Jun 9, 2023	Form 4	Cerus CERS	Filing · EDGAR
Jun 1, 2023	Form 4	CalciMedica	Filing · EDGAR
May 24, 2023	Form 4	CalciMedica	Filing · EDGAR
May 23, 2023	Form 4	Cerus CERS	Filing · EDGAR
May 22, 2023	Form 4	CalciMedica	Filing · EDGAR
May 19, 2023	Form 4	Surrozen SRZN	Filing · EDGAR
May 18, 2023	Form 4	CalciMedica	Filing · EDGAR
Apr 5, 2023	Form 3	Surrozen SRZN	Filing · EDGAR
Mar 27, 2023	Form 4	CalciMedica	Filing · EDGAR
Feb 15, 2023	Form 4	Chinook Therapeutics	Filing · EDGAR
Feb 2, 2023	Form 4	Chinook Therapeutics	Filing · EDGAR
Dec 2, 2022	Form 4	Chinook Therapeutics	Filing · EDGAR
Jun 3, 2022	Form 4	CalciMedica	Filing · EDGAR
Jun 3, 2022	Form 4	Cerus CERS	Filing · EDGAR
Feb 14, 2022	Form 4	Chinook Therapeutics	Filing · EDGAR
Feb 2, 2022	Form 4	Chinook Therapeutics	Filing · EDGAR
Dec 3, 2021	Form 4	Chinook Therapeutics	Filing · EDGAR
Jun 4, 2021	Form 4	CalciMedica	Filing · EDGAR
Jun 3, 2021	Form 4	Cerus CERS	Filing · EDGAR
Feb 12, 2021	Form 4	Chinook Therapeutics	Filing · EDGAR
Dec 18, 2020	Form 4	Chinook Therapeutics	Filing · EDGAR
Nov 17, 2020	Form 3	Chinook Therapeutics	Filing · EDGAR
Oct 14, 2020	Form 4	Aimmune Therapeutics	Filing · EDGAR
Oct 6, 2020	Form 4	Cerus CERS	Filing · EDGAR
Oct 5, 2020	Form 4	Aimmune Therapeutics	Filing · EDGAR
Sep 28, 2020	Form 4	CalciMedica	Filing · EDGAR
Sep 24, 2020	Form 3	CalciMedica	Filing · EDGAR
Sep 16, 2020	Form 4	Aimmune Therapeutics	Filing · EDGAR
Jun 5, 2020	Form 4	Cerus CERS	Filing · EDGAR
May 12, 2020	Form 4	Aimmune Therapeutics	Filing · EDGAR
Mar 12, 2020	Form 4	Aimmune Therapeutics	Filing · EDGAR
Mar 10, 2020	Form 4	Aimmune Therapeutics	Filing · EDGAR
Mar 4, 2020	Form 4	Aimmune Therapeutics	Filing · EDGAR
Mar 3, 2020	Form 4	Aimmune Therapeutics	Filing · EDGAR
Feb 14, 2020	Form 5	Aimmune Therapeutics	Filing · EDGAR
Feb 3, 2020	Form 4	Cerus CERS	Filing · EDGAR
Oct 4, 2019	Form 4	Cerus CERS	Filing · EDGAR
Sep 20, 2019	Form 4	Aimmune Therapeutics	Filing · EDGAR
Jun 7, 2019	Form 4	Cerus CERS	Filing · EDGAR
Feb 26, 2019	Form 4	Aimmune Therapeutics	Filing · EDGAR
Nov 28, 2018	Form 4	Corium International	Filing · EDGAR
Oct 9, 2018	Form 4	Cerus CERS	Filing · EDGAR
Oct 9, 2018	Form 3	Cerus CERS	Filing · EDGAR
Jun 14, 2018	Form 4	Aimmune Therapeutics	Filing · EDGAR
Mar 6, 2018	Form 4	Aimmune Therapeutics	Filing · EDGAR
Feb 26, 2018	Form 4	Aimmune Therapeutics	Filing · EDGAR
Dec 5, 2017	Form 4	Corium International	Filing · EDGAR
May 15, 2017	Form 4	Aimmune Therapeutics	Filing · EDGAR
May 1, 2017	Form 4	Aimmune Therapeutics	Filing · EDGAR
May 1, 2017	Form 3	Aimmune Therapeutics	Filing · EDGAR
Dec 27, 2016	Form 4	Corium International	Filing · EDGAR
Dec 6, 2016	Form 4/A	Sunesis Pharmaceuticals	Filing · EDGAR
Dec 2, 2016	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
May 20, 2016	Form 4	Corium International	Filing · EDGAR
Mar 2, 2016	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Jan 5, 2016	Form 4	Stemcells	Filing · EDGAR
Dec 22, 2015	Form 4	Corium International	Filing · EDGAR
Dec 2, 2015	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Jul 28, 2015	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Apr 16, 2015	Form 4	Corium International	Filing · EDGAR
Apr 1, 2015	Form 3	Corium International	Filing · EDGAR
Mar 2, 2015	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Jan 5, 2015	Form 4	Stemcells	Filing · EDGAR
Nov 3, 2014	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Aug 29, 2014	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 4, 2014	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Jan 10, 2014	Form 4	Stemcells	Filing · EDGAR
Mar 4, 2013	Form 4	Stemcells	Filing · EDGAR
Mar 1, 2013	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Apr 20, 2012	Form 4	Stemcells	Filing · EDGAR
Mar 2, 2012	Form 4	Stemcells	Filing · EDGAR
Mar 2, 2012	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Jul 5, 2011	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 2, 2011	Form 4	Stemcells	Filing · EDGAR
Mar 2, 2011	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Oct 8, 2010	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Aug 3, 2010	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Jul 1, 2010	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 3, 2010	Form 4	Stemcells	Filing · EDGAR
Nov 3, 2009	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Sep 2, 2009	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Apr 6, 2009	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 3, 2009	Form 4	Stemcells	Filing · EDGAR
Jul 2, 2008	Form 4/A	Sunesis Pharmaceuticals	Filing · EDGAR
Jul 2, 2008	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 4, 2008	Form 4	Stemcells	Filing · EDGAR
Sep 14, 2007	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 14, 2007	Form 4/A	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 13, 2007	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 8, 2007	Form 4/A	Stemcells	Filing · EDGAR
Mar 5, 2007	Form 4	Stemcells	Filing · EDGAR
Oct 17, 2006	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 1, 2006	Form 4	Stemcells	Filing · EDGAR
Dec 1, 2005	Form 4	Sunesis Pharmaceuticals	Filing · EDGAR
Sep 27, 2005	Form 3	Sunesis Pharmaceuticals	Filing · EDGAR
Mar 1, 2005	Form 4	Stemcells	Filing · EDGAR
Mar 3, 2004	Form 3	Stemcells	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 12:43 AM ET. The filing on SEC.gov is the record.